HC Wainwright Issues Pessimistic Forecast for PDSB Earnings

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Stock analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for PDS Biotechnology in a research report issued on Wednesday, June 11th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.25) for the quarter, down from their previous estimate of ($0.22). HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology's Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($0.92) EPS.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04.

Separately, Wall Street Zen raised shares of PDS Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th.

PDS Biotechnology Trading Down 2.2%

PDSB traded down $0.04 during trading on Friday, reaching $1.75. The company had a trading volume of 327,198 shares, compared to its average volume of 495,959. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The business has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $1.47. The stock has a market cap of $79.99 million, a P/E ratio of -1.51 and a beta of 1.27. PDS Biotechnology has a 52 week low of $0.85 and a 52 week high of $4.42.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in PDS Biotechnology during the 4th quarter valued at $26,000. Virtu Financial LLC bought a new stake in shares of PDS Biotechnology during the fourth quarter worth $89,000. Blair William & Co. IL boosted its stake in shares of PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock valued at $257,000 after purchasing an additional 35,757 shares during the period. Renaissance Technologies LLC grew its holdings in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock worth $163,000 after purchasing an additional 76,800 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock worth $64,000 after purchasing an additional 10,837 shares during the last quarter. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.